Avanza Fonder AB Acquires New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Avanza Fonder AB bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 10,408 shares of the biopharmaceutical company's stock, valued at approximately $7,414,000.

Several other hedge funds have also recently modified their holdings of REGN. Adirondack Trust Co. increased its stake in shares of Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company's stock worth $453,000 after purchasing an additional 10 shares during the last quarter. UMB Bank n.a. increased its stake in shares of Regeneron Pharmaceuticals by 1.1% during the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company's stock worth $955,000 after purchasing an additional 10 shares during the last quarter. Trust Co. of Vermont increased its stake in shares of Regeneron Pharmaceuticals by 8.3% during the 3rd quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company's stock worth $165,000 after purchasing an additional 12 shares during the last quarter. Brighton Jones LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.5% during the 2nd quarter. Brighton Jones LLC now owns 920 shares of the biopharmaceutical company's stock worth $967,000 after purchasing an additional 14 shares during the last quarter. Finally, Nvwm LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.4% during the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company's stock worth $1,039,000 after purchasing an additional 14 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent research reports. Leerink Partners reiterated a "market perform" rating and issued a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. UBS Group lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $1,130.00 to $738.00 in a research note on Thursday. StockNews.com lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 4th. Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. Finally, Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $1,015.38.

Regeneron Pharmaceuticals Trading Down 1.7 %

Shares of NASDAQ REGN traded down $11.65 during midday trading on Friday, hitting $681.58. 1,107,622 shares of the company traded hands, compared to its average volume of 678,713. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a 50-day moving average price of $738.60 and a 200 day moving average price of $949.99. The firm has a market cap of $74.90 billion, a P/E ratio of 16.87, a P/E/G ratio of 1.60 and a beta of 0.10.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.